Transdermal [Regulatives / Guidelines]

posted by Kelen – Brazil, 2020-06-29 16:51 (211 d 16:36 ago) – Posting: # 21605
Views: 696

Hi everyone,
In Brazil we are implementing the guideline about generic transdermal products and I have some doubts about the EMA Guideline.

(1) About the sensitisation and irritation test, is it dependent on how the medication is used or should it always be done as described in the guide, a patch every day even if the patch is to be used for more than 24 hours?

(2) Is a multiple dose study necessary if accumulation is observed or is there any other condition that would dispense this study with transdermal patches?

I would appreciate a lot any kind of help.
Thanks in advance!

Kelen

Complete thread:

Activity
 Admin contact
21,316 posts in 4,446 threads, 1,489 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Wednesday 09:27 UTC (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5